Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cancer Res. 2021 Apr 28;81(13):3580–3592. doi: 10.1158/0008-5472.CAN-20-2773

Figure 2: EGF induces TAZ expression through EGFR and its downstream signaling molecules.

Figure 2:

A and B: GBM1B cells were treated with +/− Erlotinib or Gefitinib (10 μM, 16 hours) in growth factor-depleted medium followed by EGF treatment for the indicated times. TAZ western blotting was performed using total protein lysates (A) or proteins from the nuclear and cytosol fractions (B).

C - E: GBM1B cells were treated with or without the inhibitors as marked for 16 hours in growth factor-depleted medium followed by 4-hour EGF stimulation (5,15-DPP: 100 μM; PD98059: 20 μM; Akti-1/2: 20 μM). Total protein lysates were subjected to western blotting for TAZ and other proteins.

F: ChIP-PCR using STAT3 antibody and control IgG showed the interaction between STAT3 and a putative STAT3-binding site on the TAZ promoter (−500bp to the TSS).

Protein fold expression normalized to β-Actin is shown below each lane. Data are represented as mean ± SEM (*: p < 0.01).